- Vistin Pharma has acquired a 15% stake in CF Pharma. The total price of the deal is made up of a starting price plus an additional payment, all adding up to no more than €1.6 million.
Vistin Pharma, a Norwegian pharmaceutical company specialised in producing Metformin Hydrochloride (API), has announced the acquisition of a 15% stake in CF Pharma, an API CDMO based in Budapest, Hungary.
CF Pharma specialized in the development and manufacturing of high-quality and complex APIs, have five APIs available in the market and are working on eight more.
Magnus Tolleshaug, CEO of Vistin Pharma, expressed his satisfaction with the deal, stating, “I am very pleased to announce that Vistin Pharma now has acquired a minority stake in CF Pharma. We see this as a first agreed step in a potential closer partnership in the future, which can broaden our product portfolio and form an important basis for future growth.”
Overview of outsourcing trends 
